130 related articles for article (PubMed ID: 30036351)
1. Apalutamide (Erleada) for prostate cancer.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
[No Abstract] [Full Text] [Related]
2. Apalutamide: First Global Approval.
Al-Salama ZT
Drugs; 2018 Apr; 78(6):699-705. PubMed ID: 29626324
[TBL] [Abstract][Full Text] [Related]
3. Apalutamide and its use in the treatment of prostate cancer.
Borno HT; Small EJ
Future Oncol; 2019 Feb; 15(6):591-599. PubMed ID: 30426794
[TBL] [Abstract][Full Text] [Related]
4. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
5. Darolutamide (Nubeqa) for prostate cancer.
Med Lett Drugs Ther; 2019 Dec; 61(1587):201-202. PubMed ID: 31999669
[No Abstract] [Full Text] [Related]
6. Apalutamide shows efficacy in prostate cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e149. PubMed ID: 29456088
[No Abstract] [Full Text] [Related]
7. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
8. Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
Beaver JA; Kluetz PG; Pazdur R
N Engl J Med; 2018 Jun; 378(26):2458-2460. PubMed ID: 29949489
[No Abstract] [Full Text] [Related]
9. The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy.
Barata P; Swami U; Agarwal N
Expert Rev Anticancer Ther; 2020 Mar; 20(3):147-150. PubMed ID: 32068456
[No Abstract] [Full Text] [Related]
10. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
Aschenbrenner DS
Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
[No Abstract] [Full Text] [Related]
11. Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?
Higano C
Nat Rev Urol; 2019 Jun; 16(6):335-336. PubMed ID: 31040439
[No Abstract] [Full Text] [Related]
12. Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Zang Z; Wang Z; Chiong E
Int J Urol; 2022 Jun; 29(6):541. PubMed ID: 35384091
[No Abstract] [Full Text] [Related]
13. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
Rathkopf DE; Antonarakis ES; Shore ND; Tutrone RF; Alumkal JJ; Ryan CJ; Saleh M; Hauke RJ; Bandekar R; Maneval EC; de Boer CJ; Yu MK; Scher HI
Clin Cancer Res; 2017 Jul; 23(14):3544-3551. PubMed ID: 28213364
[No Abstract] [Full Text] [Related]
14. Degarelix (firmagon) for prostate cancer.
Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
[No Abstract] [Full Text] [Related]
15. Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer?
Reis LO
Eur Urol; 2018 Nov; 74(5):682-683. PubMed ID: 30170874
[No Abstract] [Full Text] [Related]
16. ARNEO: neoadjuvant degarelix + apalutamide before surgery for high-risk prostate cancer.
Fenner A
Nat Rev Urol; 2022 Nov; 19(11):634. PubMed ID: 36195722
[No Abstract] [Full Text] [Related]
17. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO].
Rexer H; Graefen M
Urologe A; 2017 Feb; 56(2):243-244. PubMed ID: 28144693
[No Abstract] [Full Text] [Related]
18. Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
Sasaki D; Hatakeyama S; Tanaka T; Okamoto T; Yoneyama T; Ohyama C
Int J Urol; 2022 Jul; 29(7):772-773. PubMed ID: 35285092
[No Abstract] [Full Text] [Related]
19. [Apalutamide for metastatic, castration-sensitive prostate cancer].
Thomas C
Urologe A; 2019 Dec; 58(12):1496-1497. PubMed ID: 31712857
[No Abstract] [Full Text] [Related]
20. [New treatment option-apalutamide for nonmetastatic, castration-resistant prostate cancer].
Hadaschik B; Panic A
Urologe A; 2018 Jun; 57(6):729-730. PubMed ID: 29789876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
